Structure‐based approach to pharmacophore identification, in silico screening, and three‐dimensional quantitative structure–activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function

We have employed a structure‐based three‐dimensional quantitative structure–activity relationship (3D‐QSAR) approach to predict the biochemical activity for inhibitors of T. cruzi dihydrofolate reductase‐thymidylate synthase (DHFR‐TS). Crystal structures of complexes of the enzyme with eight different inhibitors of the DHFR activity together with the structure in the substrate‐free state (DHFR domain) were used to validate and refine docking poses of ligands that constitute likely active conformations. Structural information from these complexes formed the basis for the structure‐based alignment used as input for the QSAR study. Contrary to indirect ligand‐based approaches the strategy described here employs a direct receptor‐based approach. The goal is to generate a library of selective lead inhibitors for further development as antiparasitic agents. 3D‐QSAR models were obtained for T. cruzi DHFR‐TS (30 inhibitors in learning set) and human DHFR (36 inhibitors in learning set) that show a very good agreement between experimental and predicted enzyme inhibition data. For crossvalidation of the QSAR model(s), we have used the 10% leave‐one‐out method. The derived 3D‐QSAR models were tested against a few selected compounds (a small test set of six inhibitors for each enzyme) with known activity, which were not part of the learning set, and the quality of prediction of the initial 3D‐QSAR models demonstrated that such studies are feasible. Further refinement of the models through integration of additional activity data and optimization of reliable docking poses is expected to lead to an improved predictive ability. Proteins 2008. © 2008 Wiley‐Liss, Inc.

[1]  R. Docampo Recent developments in the chemotherapy of Chagas disease. , 2001, Current pharmaceutical design.

[2]  B. Schweitzer,et al.  Dihydrofolate reductase as a therapeutic target , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Aniko Simon,et al.  eHiTS: a new fast, exhaustive flexible ligand docking system. , 2007, Journal of molecular graphics & modelling.

[4]  J. Gasteiger,et al.  FROM ATOMS AND BONDS TO THREE-DIMENSIONAL ATOMIC COORDINATES : AUTOMATIC MODEL BUILDERS , 1993 .

[5]  S. Queener,et al.  Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain. , 2005, Journal of medicinal chemistry.

[6]  G. Kellogg Molecular Modeling: Basic Principles and Applications. 2nd Edition By Hans-Dieter Höltje, Wolfgang Sippl, Didier Rognan, and Gerd Folkers. Wiley-VCH, Weinheim, Germany. 2003. xii + 228 pp. 17 × 24 cm. ISBN 3527305890 (Paperback). $50.00. , 2004 .

[7]  Robert C. Reynolds,et al.  Antimycobacterial Activities of 2,4-Diamino-5-Deazapteridine Derivatives and Effects on Mycobacterial Dihydrofolate Reductase , 2000, Antimicrobial Agents and Chemotherapy.

[8]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[9]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[10]  Mitchell A. Avery,et al.  Comparison of 3D quantitative structure-activity relationship methods: Analysis of the in vitro antimalarial activity of 154 artemisinin analogues by hypothetical active-site lattice and comparative molecular field analysis , 1998, J. Comput. Aided Mol. Des..

[11]  Amy C Anderson,et al.  Towards in silico lead optimization: Scores from ensembles of protein/ligand conformations reliably correlate with biological activity , 2006, Proteins.

[12]  M. Zvelebil,et al.  Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase. , 2001, European journal of medicinal chemistry.

[13]  Erin S. Bolstad,et al.  Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis. , 2007, Journal of medicinal chemistry.

[14]  Vivian Cody,et al.  Structure determination of tetrahydroquinazoline antifolates in complex with human and Pneumocystis carinii dihydrofolate reductase: correlations between enzyme selectivity and stereochemistry. , 2004, Acta crystallographica. Section D, Biological crystallography.

[15]  H. Bernhard Schlegel,et al.  Geometry optimization methods for modeling large molecules , 2003 .

[16]  Thierry Langer,et al.  Pharmacophore Identification, in Silico Screening, and Virtual Library Design for Inhibitors of the Human Factor Xa , 2005, J. Chem. Inf. Model..

[17]  L. Kuyper,et al.  Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines. , 1995, Journal of medicinal chemistry.

[18]  S. Croft,et al.  The current status of antiparasite chemotherapy , 1997, Parasitology.

[19]  J. Apostolakis,et al.  Evaluation of a fast implicit solvent model for molecular dynamics simulations , 2002, Proteins.

[20]  S. Queener,et al.  Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS. , 2003, Journal of medicinal chemistry.

[21]  Asim Kumar Debnath,et al.  Pharmacophore mapping of a series of 2,4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase. , 2002, Journal of medicinal chemistry.

[22]  Ian H. Gilbert,et al.  Dihydrofolate reductase: A potential drug target in trypanosomes and leishmania , 1998, J. Comput. Aided Mol. Des..

[23]  P. Olliaro,et al.  Associate Editor: P. Winstanley An Overview of Chemotherapeutic Targets for Antimalarial Drug Discovery , 1999 .

[24]  I. Gilbert,et al.  2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductase. , 2003, Bioorganic & medicinal chemistry.

[25]  S. Queener,et al.  Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase. , 2004, Journal of medicinal chemistry.

[26]  J. Clardy,et al.  Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase. , 2006, Bioorganic & medicinal chemistry letters.

[27]  S. D. de Castro,et al.  A critical review on Chagas disease chemotherapy. , 2002, Memorias do Instituto Oswaldo Cruz.

[28]  Hans-Dieter Höltje,et al.  Structure-based 3D-QSAR—merging the accuracy of structure-based alignments with the computational efficiency of ligand-based methods , 2000 .

[29]  A. Doweyko,et al.  Three-dimensional pharmacophores from binding data. , 1994, Journal of medicinal chemistry.

[30]  R. Dayam,et al.  Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore. , 2007, Bioorganic & medicinal chemistry.

[31]  D. Chattopadhyay,et al.  Lipophilic Antifolate Trimetrexate Is a Potent Inhibitor of Trypanosoma cruzi: Prospect for Chemotherapy of Chagas' Disease , 2005, Antimicrobial Agents and Chemotherapy.

[32]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[33]  Aniko Simon,et al.  eHiTS: an innovative approach to the docking and scoring function problems. , 2006, Current protein & peptide science.

[34]  Wolfgang Sippl,et al.  Development of biologically active compounds by combining 3D QSAR and structure-based design methods , 2002, J. Comput. Aided Mol. Des..

[35]  F Darvas,et al.  Prediction of distribution coefficient from structure. 1. Estimation method. , 1997, Journal of pharmaceutical sciences.